HemOnc Today


The following articles appeared in the print edition of HEMONC TODAY.

Table of Contents

European Society for Radiotherapy and Oncology honors Karmanos Cancer Institute professor

ASH chooses minority resident hematology award program participants

Brentuximab vedotin shows promise in frontline chemotherapy regimen for Hodgkin lymphoma

CTL019 induces durable responses in diffuse large B-cell lymphoma

American Society for Radiation Oncology names gold medalists

University of Kansas appoints medical oncology division director

Hallucinogenic drug may ease anxiety, depressive symptoms in patients with cancer

Roswell Park Cancer Institute names chair of urology

Cover Story

Answers to ’critical questions’ may personalize treatment of HPV–associated head, neck cancer


Stem cell transplantation and CMS: Extreme (hospital at) home makeover

John Sweetenham, MD

FDA News

FDA places clinical hold on three trials of Keytruda for myeloma

FDA grants priority review to Opdivo for advanced liver cancer

FDA grants breakthrough therapy designation to burtomab for pediatric neuroblastoma

FDA approves Tafinlar plus Mekinist for BRAF V600E–mutant non–small cell lung cancer

FDA approves BevyxXa for prevention of venous thromboembolism

In the Journals Plus

Uterine lavage fluid analysis may be used as screening method for endometrial cancer

Exposure to poor environmental quality increases cancer incidence

Rivaroxaban safe, effective alternative for unprovoked VTE

Rising cancer drug costs counteract financial relief for Medicare recipients

Rare cancers represent 20% of US cancer diagnoses

Concurrent chemoradiotherapy extends OS for bladder cancer in elderly patients

Blood transfusions may increase risk for HCC, non-Hodgkin lymphoma

Blinatumomab extends OS for patients with relapsed, refractory ALL

Meeting News

KTE-C19 may safely treat relapsed, refractory ALL

PEGPH20 extends PFS in metastatic pancreatic ductal adenocarcinoma

Olaparib significantly prolongs PFS in metastatic BRCA–related breast cancer

Selumetinib effective for pediatric low-grade glioma

Abiraterone acetate with prednisone reduces risk for prostate cancer death

Pembrolizumab plus reduced-dose ipilimumab confers durable antitumor activity in advanced melanoma

Pembrolizumab shows promise in metastatic triple-negative breast cancer

Ixazomib combination confers durable responses in newly diagnosed myeloma

Daratumumab improves outcomes in relapsed, refractory myeloma

Dacomitinib superior to gefitinib for EGFR-positive NSCLC

Enzyme activator could be ‘disease-modifying’ treatment for pyruvate kinase deficiency

Elotuzumab yields durable long-term responses in myeloma


Can chemotherapy be omitted from treatment for HPV–associated head and neck cancer?